410 related articles for article (PubMed ID: 31487030)
21. Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses.
Zhao B; Wang Y; Wang Y; Chen W; Zhou L; Liu PH; Kong Z; Dai C; Wang Y; Ma W
Aging (Albany NY); 2020 Jul; 12(14):14244-14270. PubMed ID: 32669477
[TBL] [Abstract][Full Text] [Related]
22. Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis.
Hyun DG; Choi CM; Lee DH; Kim SW; Yoon S; Kim WS; Ji W; Lee JC
PLoS One; 2020; 15(4):e0231546. PubMed ID: 32298306
[TBL] [Abstract][Full Text] [Related]
23. Early Gamma Knife stereotactic radiosurgery to the tumor bed of resected brain metastasis for improved local control.
Iorio-Morin C; Masson-Côté L; Ezahr Y; Blanchard J; Ebacher A; Mathieu D
J Neurosurg; 2014 Dec; 121 Suppl():69-74. PubMed ID: 25434939
[TBL] [Abstract][Full Text] [Related]
24. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.
Doherty MK; Korpanty GJ; Tomasini P; Alizadeh M; Jao K; Labbé C; Mascaux CM; Martin P; Kamel-Reid S; Tsao MS; Pintilie M; Liu G; Bradbury PA; Feld R; Leighl NB; Chung C; Shepherd FA
Radiother Oncol; 2017 May; 123(2):195-202. PubMed ID: 28363487
[TBL] [Abstract][Full Text] [Related]
25. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
Yu X; Sheng J; Pan G; Fan Y
Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2-9 versus 10 or more tumors.
Yamamoto M; Kawabe T; Sato Y; Higuchi Y; Nariai T; Watanabe S; Kasuya H
J Neurosurg; 2014 Dec; 121 Suppl():16-25. PubMed ID: 25434933
[TBL] [Abstract][Full Text] [Related]
27. Is it advisable to perform radiosurgery for EGFR-TKI-controlled brain metastases? A retrospective study of the role of radiosurgery in lung cancer treatment.
Hung JS; Su YH; Chen CJ; Chiang CL; Shen CI; Yang HC; Shiau CY; Luo YH; Wu HM; Hu YS; Lin CJ; Liu KD; Chung WY; Guo WY; Lee CC
J Neurooncol; 2023 Sep; 164(2):413-422. PubMed ID: 37656378
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant.
Zhao L; Cai X; Chen D; Ye X; Gao M; Lu L; Su H; Su M; Hou M; Xie C
Radiat Oncol; 2019 Dec; 15(1):3. PubMed ID: 31892337
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy.
Caballero JA; Sneed PK; Lamborn KR; Ma L; Denduluri S; Nakamura JL; Barani IJ; McDermott MW
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):303-9. PubMed ID: 22079723
[TBL] [Abstract][Full Text] [Related]
30. Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.
Gerber NK; Yamada Y; Rimner A; Shi W; Riely GJ; Beal K; Yu HA; Chan TA; Zhang Z; Wu AJ
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):322-9. PubMed ID: 24679729
[TBL] [Abstract][Full Text] [Related]
31. ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI.
Chan OSH; Lam KC; Li JYC; Choi FPT; Wong CYH; Chang ATY; Mo FKF; Wang K; Yeung RMW; Mok TSK
Lung Cancer; 2020 Apr; 142():41-46. PubMed ID: 32088604
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study.
Wang X; Zeng Z; Cai J; Xu P; Liang P; Luo Y; Liu A
BMC Cancer; 2021 Apr; 21(1):482. PubMed ID: 33931014
[TBL] [Abstract][Full Text] [Related]
33. EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases.
Liao HR; Chiang CL; Shen CI; Chen CJ; Yang HC; Wu HM; Luo YH; Hu YS; Lin CJ; Chung WY; Shiau CY; Guo WY; Pan DH; Lee CC
J Neurooncol; 2022 Sep; 159(3):675-684. PubMed ID: 35976545
[TBL] [Abstract][Full Text] [Related]
34. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
35. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
36. Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors.
Lee JH; Chen HY; Hsu FM; Chen JS; Liao WY; Shih JY; Yu CJ; Chen KY; Tsai TH; Yang JC
Oncologist; 2019 Dec; 24(12):e1417-e1425. PubMed ID: 31127020
[TBL] [Abstract][Full Text] [Related]
37. Combined stereotactic radiosurgery and tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone for the treatment of non-small cell lung cancer patients with brain metastases.
Chiou GY; Chiang CL; Yang HC; Shen CI; Wu HM; Chen YW; Chen CJ; Luo YH; Hu YS; Lin CJ; Chung WY; Shiau CY; Guo WY; Pan DH; Lee CC
J Neurosurg; 2022 Aug; 137(2):563-570. PubMed ID: 34920439
[TBL] [Abstract][Full Text] [Related]
38. Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.
Sun Y; Wu M; Zhou M; Luo X; Guo Y; Bai H; Zhang Z; Tian W; Wang X; Bai Y; Zhu X; Pan H; Deng Y; Hu H; Xia J; Hao X; Han L; Wei M; Liu Y; Zeng M
BMC Cancer; 2020 Jul; 20(1):646. PubMed ID: 32660443
[TBL] [Abstract][Full Text] [Related]
39. Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor.
Kwon BS; Cho YH; Yoon SK; Lee DH; Kim SW; Kwon DH; Lee JC; Choi CM
Thorac Cancer; 2020 Feb; 11(2):436-442. PubMed ID: 31910497
[TBL] [Abstract][Full Text] [Related]
40. A new grading system focusing on neurological outcomes for brain metastases treated with stereotactic radiosurgery: the modified Basic Score for Brain Metastases.
Serizawa T; Higuchi Y; Nagano O; Matsuda S; Ono J; Saeki N; Hirai T; Miyakawa A; Shibamoto Y
J Neurosurg; 2014 Dec; 121 Suppl():35-43. PubMed ID: 25434935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
